EG — Everest Group, Ltd.

The market is cautiously constructive but not enthusiastic: 8 Buy ratings versus 14 Holds, no Sells, and an average price target near $402-404 versus $377.66. Recent Q2 2026 strength, an improved operating ROE, and a $395m buyback support sentiment, but those are offset by negative top-line growth and softening global reinsurance pricing.

Revenue has clearly decelerated: H1 2026 revenue was $8.03B versus $8.64B in H1 2025, down about 7.1%, and Q2 2026 revenue fell ~10.1% YoY. Earnings are lumpy rather than steadily trending: Q2 2026 EPS was $13.88 versus $16.10 a year earlier, Q1 2026 was $16.21, but Q4 2024 was -$13.80 and Q1/Q3 2025 were weak at $4.90/$6.09. Q2 2026 operating margin improved to roughly 23.8% on $944m operating income, up from 18.5% in Q2 2025. This is a portfolio-inflection story: management is pruning underperforming retail/casualty lines, so part of the volume decline is intentional.

As of 2026-08-27, the stock is cheap on the numbers: trailing P/E of 8.04, P/B of 0.986, P/S of 0.895, and a forward P/E near 7.0x based on next-fiscal-year consensus EPS of $53.54. Those multiples sit well below EG's 5-year average P/E of 11.19 and average P/S of 0.95. The low PEG of 0.055 is not meaningful for a volatile reinsurer. The discount is partly justified by soft pricing, but the valuation is not demanding.

At $377.66 as of 2026-08-27, the market is paying roughly 7.1x next-fiscal-year consensus EPS of $53.54. That is not pricing in meaningful growth; it is paying a single-digit multiple for underwriting discipline and balance-sheet quality. If Q3-Q4 2026 hold near a 92% combined ratio and buybacks continue, EPS could beat $53.54 and the multiple could re-rate toward 8-9x, creating upside. If reinsurance pricing keeps falling, estimates will drift lower and the low multiple will look fair rather than cheap.

As of 2026-08-27, RSI was 55.99, price was 1.88% above the 20-day SMA, 2.41% above the 50-day SMA, and 10.68% above the 200-day SMA. That is a healthy uptrend but not overbought, and the stock sits toward the top of its 302.44-401.07 52-week range. Implication: the trend is supportive, but the better risk/reward is on a pullback toward the 50-day rather than chasing at $378.

• Global reinsurance pricing is softening, with Fitch flagging roughly 6% YoY rate declines as abundant capital and competition pressure the sector.
• Elevated interest rates support reinsurers' investment income and bond portfolio yields, though future rate cuts would slowly reduce that tailwind.
• Natural catastrophe frequency/severity and geopolitical conflict losses can swing quarterly results; Q2 2026 cat losses were manageable at around $75m.
• Capital deployment is a major driver: $395m of buybacks in Q2 and the $2.00 quarterly dividend support per-share value even as revenue shrinks.
• Portfolio reshaping through divestitures of Mexico, Colombia, and Canada operations, plus the Annapurna Re sidecar, shifts the business toward core reinsurance and away from volatile retail lines.

• Q3 2026 earnings, expected late October/early November 2026, as evidence on whether the core combined ratio stays near 90-92% and portfolio contraction is stabilizing.
• January 1, 2027 reinsurance renewals, which will determine whether pricing declines are decelerating or accelerating.
• Regulatory completion of the Mexico sale to Fairfax and continued aggressive buyback execution.
• Any large catastrophe or reserve development event would either reinforce or undermine confidence in underwriting quality.

• Reinsurance rate softening is the biggest structural risk: if pricing keeps falling, deliberate volume cuts may not be fully offset by margin gains.
• Catastrophe losses and adverse reserve development are inherent to reinsurance; a bad Q3 or Q4 can erase a year of underwriting profit.
• Execution risk in shrinking the retail portfolio could reduce future float, investment income, or client relationships.
• Interest rate and credit market moves can hit the large investment portfolio, which supports $62.2B total assets against $15.4B equity.

Everest is a well-capitalized, cheap reinsurer with improving underwriting discipline and aggressive shareholder returns, but the fundamental score is weak because trailing growth is negative and the pricing cycle is turning softer. For a patient value investor the risk/reward is attractive at roughly 7x forward earnings and 1x book; for a momentum investor the top-line contraction and Hold consensus argue against chasing. Overall, cautious.

Applied a justified forward P/E of 8.0x to consensus next-fiscal-year EPS of $53.54; 8.0x is well below EG's 5-year average P/E of 11.19 and reflects the softening reinsurance cycle and top-line contraction, while being slightly above the current ~7.0x forward multiple to reflect continued underwriting discipline and buybacks. A cross-check at roughly 1.1x book value on ~$399 BVPS gives about $439, supporting the $428 area.